Phase II trial of titanocene dichloride in advanced renal-cell carcinoma
Phase II trial of titanocene dichloride in advanced renal-cell carcinoma
复制标题
DOI：
10.1007/s002800050838
复制
发表时间：
1998-10-01
影响因子：
3
通讯作者：
Rübben, H
中科院分区：
文献类型：
--
作者：
Lümmen, G;Sperling, H;Rübben, H
二氯二茂钛在体外能够抑制不同类型的人类肿瘤的生长。共有14例转移性肾细胞癌（RCC）患者接受270 mg/m2二氯二茂钛，每3周1次，共6周。虽然所遇到的毒性和副作用是轻度至中度的，但未检测到部分或完全反应。结论：二氯二茂钛在治疗肾细胞癌方面无优势。
Titanocene dichloride was capable of inhibiting the growth of different types of human tumors in vitro. A total of 14 patients with metastatic renal-cell carcinoma (RCC) received 270 mg/m(2) titanocene dichloride every 3 weeks for 6 weeks. Although the toxicities and side effects encountered were mild to moderate, no partial or complete response was detectable. In conclusion, titanocene dichloride has no advantage in the therapy of RCC.